Notably, the SMO inhibitor Vismodegib has demonstrated efficacy in inhibiting the growth of HCC in HBx transgenic mice, effectively suppressing HBx-positive human HCC xenograft tumors [31]. Here, SMO is linked to hepatocellular carcinoma.